In drug discovery research, it is essential to check daily paper information and public databases, and update knowledge and knowledge of important information.However, the number of documents is increasing year by year, and it is already difficult for humans to cover all the necessary information.
The article search AI "KIBIT Amanogawa" can instantly detect and analyze article information with high similarity and relevance from the huge amount of article information of over 3000 million articles published on Pubmed.
It makes it possible to find information that could not be found through conventional keyword searches and information that is not biased by the searcher, realizing objective and comprehensive analysis in medical and drug discovery research.

●“KIBIT Amanogawa, a discovery-type concept search AI system specializing in hypothesis generation”
In this section, we will introduce an overview of the AI ​​algorithms and systems installed in KIBIT Amanogawa.

●“Hypothesis generation method and new usage examples using paper search AI for researchers”
In this section, we will introduce how KIBIT Amanogawa is actually used by drug discovery researchers to generate hypotheses, and how to approach it, along with new analysis examples.

[Date and time] October 2023, 11 (Tuesday) 28:11~40:12
Trial session (only for those participating at the real venue): Tuesday, November 2023, 11, 28:12-30:13 (free to leave)

[Format] Online (Zoom Webinars) & real venue held simultaneously
*Bento and drinks will be provided at the real venue.Please join us as a luncheon seminar.

[Venue] FRONTEO Co., Ltd. Shinagawa Head Office 4th floor AI Tech Lounge
(address　 108-0075-2 Konan, Minato-ku, Tokyo 12-23 Meishan Takahama Building）
*Capacity: 20 people (first-come, first-served basis. If the capacity is exceeded, you will be placed on a waiting list for cancellations)

[Participation conditions]
We kindly ask that you refrain from applying if you are using the free address, if you are in the same industry as us, or if you do not know your affiliation.When accessing Zoom on the day, please enter your name and email address that you entered at the time of application in the entry field for Zoom participation.

FRONTEO Inc.
Executive Officer
Drug Discovery AI FactoryChief Executive Officer
Head of Life Science AI Business Headquarters and Director of Behavioral Information Science Research Institute
CTO Ph.D. (Science)
Hiroyoshi Toyoshiba

Waseda University Graduate School of Science and Engineering Department of Mathematics.Since 2000, during the doctoral course in science (mathematics, obtained a doctorate in 1999), he has been in charge of statistical analysis of medical data at the Medical Information Department of Kyushu University Hospital. Since 2000, he has participated in research on carcinogenic processes by data analysis at the National Institute of Environmental Health Sciences (NIEHS). Since 2004, he has been engaged in statistical analysis of toxicity data, design of epidemiological research, and data analysis research at the National Institute for Environmental Studies. Joined Takeda Pharmaceutical Company Limited in 2006, and has served as a researcher in the field of bioinformatics, head of the Global Data Science Institute / Japan Site Bioinformatics, and a science fellow.He is also involved in gene expression data analysis and target search in clinical trial data, as well as biomarker search in immunity and cancer.
Engaged in life science AI development at FRONTEO since 2017.He develops AI algorithms specialized in the area of ​​life sciences.Utilizing the feature of vectorization of text, we have developed various AI products based on this artificial intelligence, such as research paper search, drug discovery support, dementia diagnosis support, and fall prediction.
Life Science AI CTO since 2019. In 2021, he will be appointed as an executive officer.Further promote the social implementation of AI through a mathematical approach.

FRONTEO Inc.
Life Science AI Business Headquarters
AI drug discovery team
Ai Hakusui

Worked as a medical information representative (MR) mainly in the ophthalmology field at a foreign pharmaceutical company.
Joined FRONTEO in March 2023.Currently, he is working at the Life Science AI Business Headquarters to expand the AI ​​drug discovery business, including KIBIT Amanogawa.